LOGIN
Denosumab in THA prevents early periprosthetic bone loss, effects diminish after treatment cessation
March 2020
Denosumab in THA prevents early periprosthetic bone loss, effects diminish after treatment cessation
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Denosumab Prevents Early Periprosthetic Bone Loss After Uncemented Total Hip Arthroplasty: Results from a Randomized Placebo-Controlled Clinical Trial.
J Bone Miner Res. 2020 Feb;35(2):239-247.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Sixty-four patients scheduled for an uncemented total hip arthroplasty (THA) were randomized to receive either two doses of denosumab or placebo administered following completion of the procedure and 6 months post-operation. The primary outcomes of interest were bone mineral density (BMD) at Gruen zone 7 and the sum of BMDs in Gruen zones 1-7. Secondary outcomes of interest included standard uptak...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.